>>Medivation: Dimebon Trial Patient Subsets Improved >MDVN
Last update: 5/3/2007 1:54:19 PM
DOW JONES NEWSWIRES
Medivation Inc. (MDVN) said its Dimebon treatment for Alzheimer's disease produced statistically significant improvements in two subsets of patients in a Phase II study.
Medivation, San Francisco, said 183 patients in subsets of mild and moderate Alzheimer's disease showed improved average cognition, behavior and daily activities as well as in a measure of global function, when compared with placebo-treated patients.
The six-month study was not designed to determine the effects of Dimebon on the subgroups, which contained a relatively small number of patients.
The study was conducted at multiple sites in Russia, and patients received oral Dimebon, 20 mg three times a day or placebo.
Medivation previously announced that the same study showed overall significant improvements in Dimebon-treated patients compared with placebo treated patients in achieving primary and secondary endpoints.
The company is completing an extension of the study and expects to report results of this 12-month trial later this quarter.
-John Seward; 201-938-5400; AskNewswires@dowjones.com<<
This hasn't moved the stock. I closed my position in the low $9s a few days ago for a modest profit, as the P2 data has been trickling out already, and I'm not sure I want to be there for the full disclosure of the 12 month extension to the P2. But I will look to re-enter afteer the data comes out. Again, the real risk to MDVN share price will probably come as it goes to market. Dimebon might actually make it through the trials and the FDA. It's just that efficacy is likely to be modest at best, and I don't see how they will control the market.
Cheers, Tuck |
